To determine whether prehospital statin use is associated with a lower risk of sepsis, acute lung injury/acute respiratory distress syndrome, and mortality in critically ill patients. We also investigated the effect of combined prehospital use of both statins and aspirin.
A cute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) are common causes of acute respiratory failure with estimated frequencies in the United States of 78.9 and 58.7 cases per 100,000 person-years, respectively (1) . The mortality of these conditions approaches 40% (1) . Despite advances in critical care since the initial description of these syndromes (2) , low tidal volume ventilation remains the only specific therapy that has been proven to reduce mortality (3) .
Severe sepsis, the most common cause of ALI/ARDS, is also a common condition with high mortality and limited proven, specific therapies (4) . Since both sepsis and lung injury are prevalent and have a high mortality and limited treatment options, primary prevention may be the best way to combat these syndromes.
Despite differences in affected organ systems and clinical presentation, sepsis and ALI syndromes have similar underlying mechanisms, as they both are characterized by inflammation and endothelial dysfunction (5) (6) (7) . Although the role of the inflammatory cascade in the pathophysiology of these syndromes is well described (5) (6) (7) , clinical trials investigating the use of anti-inflammatory agents in the treatment of both ALI/ARDS (8 -10) and sepsis (11, 12) have been disappointing.
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins)
have a desirable effect on the lipid profile of most individuals. These medications have proven to be effective in both primary (13) and secondary (14) prevention of cardiovascular disease-effects that appear to be independent of effects on the lipid profile (15) . In addition to inhibition of cholesterol synthesis, statins have immunomodulatory and anti-inflammatory effects in a variety of human conditions (16 -20) . Because of these pleiotropic effects, statins have been studied as preventive therapy for noncardiovascular conditions such as cancer (21, 22) and venothromboembolism (23) with promising results. Furthermore, several observational studies have suggested that statin therapy may prevent progression to severe sepsis (24) and reduce mortality in patients with infections or bacteremia (25, 26) . Recent data reveal that preadmission statin use may reduce the risk of death among patients admitted to the intensive care unit (ICU) (27) . In addition to beneficial effects in sepsis, animal models suggest that statins may have similar protective effects in ALI/ARDS (28) ; however, an observational study did not find that statin therapy altered the course of patients with ALI/ARDS (29) .
Aspirin, through its antiplatelet effects, is the cornerstone in both the prevention and treatment of cardiovascular and cerebrovascular disease and is commonly taken in conjunction with statins for primary or secondary prevention of atherosclerotic coronary artery disease. The effect of platelets in the pathogenesis of ALI and sepsis has been studied for decades (30, 31) . Platelets are known to play an important role in mediating an animal model of sepsis-induced lung injury (32) . Platelet inhibition with aspirin attenuates the development of transfusion-related lung injury in an animal model (33) . Because of important differences in platelet/neutrophil interactions between animal models and human lung biology, the role of platelets in clinical ALI/ARDS cannot reliably be extrapolated (34) . Although preadmission aspirin use appeared to have no effect on mortality in a cohort of patients with pneumonia (35) , the effect of antiplatelet therapy with aspirin on the development of ALI syndromes has not been investigated; furthermore, prior clinical studies of statins and sepsis or ALI/ARDS did not consider the potential confounding effects of aspirin use. We performed a cross-sectional analysis of a prospectively collected cohort to test the hypothesis that prehospital use of statins is associated with lower risk of the development of severe sepsis and ALI/ARDS, as well as lower mortality, in critically ill patients. We also examined the association of aspirin use with the development of these clinical syndromes.
MATERIALS AND METHODS
Study Design. We constructed our study population using data obtained from the first 1,004 patients who were prospectively enrolled, between January 23, 2006, and April 1, 2008, in the Validating Acute Lung Injury Markers for Diagnosis (VALID) study. The VALID study was designed to develop and validate plasma biomarkers for use in diagnosis and prognosis of ALI/ARDS. The study protocol was approved by the Vanderbilt University Institutional Review Board, and written informed consent was obtained from the patient or his/her surrogate at the time of enrollment when possible. Because the study carried minimal risk to the study participants, a waiver of informed consent was granted by the Institutional Review Board.
Patients eligible for the VALID study were those aged Ն18 yrs admitted to the medical, surgical, cardiovascular, and trauma ICUs who remained in the ICU for at least 2 days. Pa-tients were excluded from enrollment into VALID if they were Ͻ18 yrs of age, were in any other hospital ICU for Ͼ3 days before enrollment, had cardiac arrest before enrollment, or died or were discharged from the ICU within 48 hrs or if transfer orders were written or anticipated to be written Ͻ4 hrs from screening and enrollment. Patients were also excluded from VALID if they were admitted to the ICU for an uncomplicated overdose or routine postoperative admission after cardiothoracic surgery or if they had a history of severe chronic lung disease, such as severe asthma, chronic obstructive pulmonary disease, or pulmonary fibrosis.
Upon enrollment into VALID, plasma and urine were collected. Clinical data, including demographics, medical history, hemodynamics, ventilator variables, medications with dosages (including prehospital medications), and laboratory values, were extracted from the medical record. Although data on the specific type of statin used were collected, for the purpose of multivariable analysis, patients on any type of prehospital statin therapy were grouped as "statin users." Severe sepsis was diagnosed by published consensus definitions (36) using clinical data from the time of en-rollment and for each of the three following days. ALI/ARDS was diagnosed in a similar manner, using published consensus definitions (37) . All chest radiographs during the first four ICU days were reviewed by at least two investigators to reach consensus on the presence or absence of bilateral pulmonary infiltrates consistent with ALI/ARDS. Adjudication of the diagnoses of severe sepsis and ALI/ARDS was made by review of all pertinent clinical data and chest radiographic findings by at least two investigators for each enrolled patient. Additional clinical data were collected upon enrollment and daily for the next 72 hrs to determine whether the patient developed organ failures (38) , severe sepsis (36), or ALI/ ARDS (37) . Neither the diagnosis of severe sepsis nor that of ALI/ARDS was dependent upon the assessment of the treating clinicians. Outcome data were also collected, including need for dialysis, duration of mechanical ventilation, duration of ICU stay, duration of hospital stay, and hospital mortality.
Inclusion/Exclusion Criteria. The first 1,004 patients enrolled into the VALID study were considered for inclusion into the cohort. To enrich the cohort for patients likely to be diagnosed with severe sepsis or ALI/ARDS, we excluded patients admitted to the trauma ICU. To avoid the confounding effects of cardiovascular disease that might be associated with both higher rates of statin use and fewer diagnoses of ALI/ARDS and sepsis, we excluded patients admitted to the cardiovascular ICU and patients admitted to any ICU with an acute cardiac diagnosis. Finally, because statin use was exceedingly rare in patients Ͻ40 yrs of age, only patients Ն40 yrs old were included.
Statistical Analysis. Univariable analyses were conducted using Wilcoxon's rank sum test for continuous variables and Fisher's exact test for categorical variables. Median values with lower and upper quartiles are reported for continuous variables, and frequencies with proportions are reported for categorical variables. Logistic regression models were developed for the rates of severe sepsis, ALI/ARDS, and death. The explanatory variables of interest were specified before data exploration. Interactions with the main variable (statin use) and other variables were investigated in an exploratory fashion; however, no compelling effects were found, and interaction terms were not considered in the models. The proportions of patients with outcomes of interest are compared on the basis of statin and aspirin use with a Cochran-Armitage test for trend. PASW Statistics (formerly SPSS, version 18.0, SPSS, Chicago, IL) was used for database management, and R 2.9.1 (39) was used for statistical analysis; a two-sided significance level of .05 was used for statistical inference.
RESULTS
Clinical Characteristics. The final population included 575 patients, 149 of whom used any statin medication before hospitalization ( Fig. 1) . Table 1 includes a comparison of baseline characteristics. Overall, the group of prehospital statin users was older and heavier, had higher serum creatinine levels, and was more likely to be diabetic, findings consistent with clinical indications for these medications and previously published reports assessing statins as prevention for sepsis and infectious-related complications (24, 25, 40) . A significantly higher percentage of prehospital statin nonusers were Caucasian. Additionally, there was an association between prehospital statin use and prehospital aspirin use. There was no difference in severity of illness (as measured by the Acute Physiology and Chronic Health Evaluation II [APACHE II] score), gender or tobacco use, presence of malignancy, or illicit drug use between statin users or nonusers.
Specific prehospital statin medications used are listed in Table 1 . In the majority of prehospital statin users (92 of 149, 61.7%), statins were not administered during the first four ICU days. Conversely, statin therapy was initiated in 13 (3.1%) of the 426 patients without known prehospital statin use. This resulted in 70 patients with in-hospital statin use during the first four ICU days. As the preferred statin on the hospital formulary is simvastatin, all but three patients (two with atorvastatin, one with pravastatin) received this medication while in the hospital.
Severe Sepsis and ALI/ARDS. (Table 3) . Additionally, we performed a univariable analysis to explore the effect of type 2 statins (atorvastatin, fluvastatin) vs. type 1 statins (lovastatin, pravastatin, simvastatin) on the diagnoses of severe sepsis and ALI/ARDS. There was a trend that patients taking type 2 statins were less likely to have the diagnosis of severe sepsis than those taking type 1 statins, although a similar finding was not appreciated on the end point of ALI/ARDS (Table 3 ). Because the diagnoses of severe sepsis and ALI/ARDS may be collinear (i.e., one leads to the other and vice versa), we explored the association of prehospital statin use on the combined end point of severe sepsis and ALI/ARDS. Of the 298 patients who met diagnostic criteria for severe sepsis during the first four ICU days, 126 (43.3%) met diagnostic criteria for ALI/ARDS as well. The combined end point of severe sepsis with ALI/ARDS occurred in 22 Fig. 3 ). The APACHE II score was significantly associated with higher risks in both models (severe sepsis, OR 2.35 for increment of 10, 95% CI 1.87-2.95; ALI/ARDS, OR 2.00 for increment of 10, 95% CI 1.57-2.53).
Among prehospital statin users, there was no statistically significant association with the discontinuation of statin therapy during the hospitalization and the subsequent diagnosis of severe sepsis or ALI/ ARDS, although the sample size was very small. As noted in Table 2 , three patients with prehospital statin use were diagnosed with severe sepsis on days 2-4 of the study period, with two of these diagnosed in patients in whom statin therapy was discontinued on enrollment. Four patients with prehospital statin use were diagnosed with ALI/ARDS on days 2-4 of the study period. All four of these patients had statin therapy discontinued on enrollment.
Association Between Prehospital Statin Use and Other Clinical Outcomes. Despite the lower prevalence of ALI/ARDS and severe sepsis in statin users, prehospital statin use had no statistically significant association with ventilator-free days, ICU length of stay, and hospital length of stay (Table 6 ). Prehospital statin users were less likely to have or develop hepatic failure (OR 0.23, 95% CI 0.12-0.45, p Ͻ .001) or coagulation failure (OR 0.39, 95% CI 0.24 -0.62, p Ͻ .001). There was no statistically significant difference in the development of circulatory failure (OR 0.90, 95% CI 0.57-1.44, p ϭ .67) or Enrollment  119  25  278  61  Day 2  16  4  11  1  Day 3  10  0  6  1  Day 4  7  0  3  1  Total  152  29 298 64 a Denotes cases diagnosed in those with prehospital statin use. The odds ratio for age is for an increment of 10 yrs. The odds ratio for the Acute Physiology and Chronic Health Evaluation II score is for an increment of 10. renal failure (OR 1.18, 95% CI 0.81-1.73, p ϭ .39).
Mortality. Of the 575 patients in our cohort, 112 (19.5%) died before discharge from the hospital. A total of 152 patients met diagnostic criteria for ALI/ARDS and 298 met diagnostic criteria for severe sep-sis within the first 4 days of ICU admission. Both of these conditions were associated with increased hospital mortality in univariable analysis; mortality was 32.9% in ALI/ARDS compared to 14.7% in those without ALI/ARDS (p Ͻ .001) and 27.9% in those with severe sepsis compared to 10.5% in those without severe sepsis (p Ͻ .001). There was no statistically significant difference in mortality between prehospital statin users and nonusers in a univariate analysis (18.1% vs. 20.0%, p ϭ .72). Stopping statin therapy in patients with prehospital statin use was not associated with increased mortality (OR 1.3, 95% CI 0.54 -3.12, p ϭ .56). In a multivariable analysis including prehospital statin use, age, gender, race, current tobacco use, prehospital aspirin use, and APACHE II score ( Table 7 , Fig. 4 ), only APACHE II was an independent predictor of mortality. An increase of 10 in the APACHE II score corresponds to doubling the odds of death (OR 2.02, 95% CI 1.56 -2.63) when other variables are held unchanged. Prehospital statin use had no significant association with hospital mortality in this model (OR 1.06, 95% CI 0.62-1.83).
Aspirin Use. In a univariable analysis, prehospital use of aspirin (either 81 mg daily or 365 mg daily) had no statistically significant association with death, diagnosis of ALI/ARDS, or diagnosis of severe sepsis. There was a statistically significant association between prehospital statin use and prehospital aspirin use, as 50.3% (75 of 149) of patients taking prehospital statins were also taking daily aspirin, while only 14.3% (61 of 426) of those not taking prehospital statins were taking daily aspirin (p Ͻ .001). Although aspirin had no association with the primary end points in univariable analysis, rates of ALI/ARDS, severe sepsis, and hospital mortality were lowest in those who received both aspirin and statins before hospitalization (Fig. 5 ). In the multivariable analyses, prehospital aspirin use did not have an independent association with the diagnosis of ALI/ARDS or sepsis or with hospital mortality (Figs. 2-4 , Tables  3, 4, and 7) .
DISCUSSION
There are several potential mechanisms for the apparent protective effect of statins in sepsis and ALI/ARDS. The efficacy of statin therapy in reducing cardiovascular risk is well established, even in patients without elevated cholesterol levels (41) . As the understanding of atherosclerosis as an inflammatory disease has progressed (42) , researchers have uncovered many mechanisms by which statins modulate the inflammatory response by decreasing inflammation (16) and attenuating endothelial dysfunction (28, 43, The odds ratio for age is for an increment of 10 yrs. The odds ratio for the Acute Physiology and Chronic Health Evaluation II score is for an increment of 10. Table 6 . Effect of prehospital statin use on ventilator days, intensive care unit length of stay, and hospital length of stay
Variable
Statin Users (n ϭ 149) Statin Nonusers (n ϭ 426) p
Ventilator days 2 (0, 7) 3 (0, 6) .72 Intensive care unit length-of-stay (days) 5 (3, 11) 6 (4, 10) .25 Hospital length of stay (days) 10 (6, 22) 12 (7, 22) .24
Data given as median (25th percentile, 75th percentile). The odds ratio for age is for an increment of 10 yrs. The odds ratio for the Acute Physiology and Chronic Health Evaluation II score is for an increment of 10. 44). Furthermore, statins have antithrombic effects (45, 46) , a mechanism supported by a large, randomized, controlled trial (23) . There are striking similarities in the pathogenesis of atherosclerosis (42), sepsis (5) , and ALI/ARDS (6), including inflammation, endothelial dysfunction, and thrombosis; the effects on any or all of these pathways may contribute to the observed beneficial effect of statins.
In this study of 575 critically patients at high risk for severe sepsis and ALI/ ARDS, prehospital use of statins was associated with a lower rate of having or developing severe sepsis or ALI/ARDS during the first 4 days in the ICU. Our study supports the hypothesis that statin therapy may prevent serious inflammatory conditions such as severe sepsis and ALI/ARDS; however, we did not find any association between prehospital statin use and in-hospital mortality in our cohort of critically ill patients.
Previous observational investigations have also found that patients receiving statin therapy have a reduced risk of developing severe sepsis (24, 40) . Although our findings are congruent with these studies, our study has important differences. Because our cohort consisted entirely of patients admitted to ICUs, the severity of illness, as determined by the APACHE II score, was substantially higher than previously published reports describing statins as protective against the development of sepsis (24) . Also, while other studies have investigated the protective effect of statins in patients with cardiovascular disease (40), we excluded patients admitted to the cardiovascular ICU and those with a primary cardiac diagnosis because this group might be less likely to have sepsis or ALI/ARDS but be more likely to have prehospital statin use.
In addition to a lower prevalence of severe sepsis, we found that prehospital statin use is associated with a lower prev-alence of ALI/ARDS in the first 4 days of critical illness-a finding that is unique to this investigation. This finding is especially noteworthy considering that prehospital or in-hospital statin use in 178 patients with ALI/ARDS did not alter the clinical course in a prior study (29) . Taken together, these findings suggest that statins might have a role in preventing the initial inflammatory response that leads to severe sepsis or ALI/ARDS rather than having a therapeutic effect once organ failure or lung injury is established. However, prospective studies are needed to better determine the effects of statins on prevention and treatment of both sepsis and ALI/ARDS since causality cannot be inferred from this observational study.
Although prehospital statin use was associated with a decreased rate of diagnosis of ALI/ARDS and severe sepsis, we detected no difference in mortality between prehospital statin users and nonusers. There are several potential explanations for this finding. First, the study was likely underpowered to detect any effect statin use may have on patient mortality. Second, we did not assess such important predictors of mortality as appropriateness or timing of initial antibiotic therapy, tidal volume, or underlying chronic medical conditions. Third, statin therapy was discontinued in the majority of patients after ICU admission; this may have led to a decline in protective effects over the course of hospitalization. Finally, ALI/ARDS and severe sepsis are syndromes that represent the clinical manifestations of severe inflammatory and metabolic dysregulation and derangement. The prevention of these clinical syndromes may not equate with preventing the underlying mechanisms that lead to patient mortality. Although there is concern that the discontinuation of statin therapy upon admission to the ICU increases mortality (47) , in our cohort, we did not make this observation.
Animal models suggest that statins may attenuate lung injury by a variety of mechanisms, including modulation of endothelial nitric oxide synthase activity (48, 49) and suppression of leukocyte adhesion and free radical generation (50). Kor et al (29) were unable to demonstrate that statin therapy affects the course of ALI/ARDS or prevents further organ failures in the setting of established disease; however, the available animal data suggest that statins may prevent lung injury, not modify the course once it has oc- curred. Furthermore, structural differences have led to the categorization of statins as either type 1 (simvastatin, lovastatin, pravastatin) or type 2 (fluvastatin, rosuvastatin, atorvastatin). These structural differences lead to differential binding of the 3-hydroxy-3-methylglutaryl coenzyme A reductase complex and may affect potency and biological activity (51, 52) . In our observations, it appears that the type 2 statins may be more protective against severe sepsis than the type 1 statins while both seem equally protective against the development of ALI/ ARDS. Although it is not possible to prove causality in an observational study, other investigations also suggest that statins may provide protection from the development of sepsis in both animal models (53) (54) (55) and humans (24, 26, 40) ; our study supports this finding in a cohort of critically ill patients admitted with noncardiac diagnoses.
In addition to the statins, aspirin, through its antiplatelet effects, has been postulated to attenuate lung injury in animal models (33, 34) . Before the current investigation, there have been no studies that have evaluated the effect of aspirin on the clinical syndromes of sepsis and ALI/ARDS, despite the fact that aspirin is commonly used in conjunction with statins for the primary or secondary prevention of coronary artery disease. Although aspirin alone did not have a significant association with development of severe sepsis or ALI/ARDS, the lowest rates of both severe sepsis and ALI/ARDS were in patients who were taking both statins and aspirin before hospitalization ( Fig. 5 ). Furthermore, mortality was significantly lower in patients taking both aspirin and statin therapy than in patients taking statins alone or neither medication (Fig. 5 ). These findings suggest that aspirin use might potentiate the protective effects of statins in severe sepsis and ALI/ARDS. However, larger prospective studies will be needed to test this hypothesis.
Because of the observational design of our study, it has several limitations. Importantly, we were unable to control the administration of statin therapy, as patients were prescribed therapy at the discretion of their outpatient physicians. Furthermore, we could control neither the specific agent administered nor the dosage prescribed, and the combinations were too varied to allow for further analysis of individual types or doses of statin drug or aspirin. Because statins are indi-cated for a number of medical conditions, this study is subject to confounding by these indications as well as the patient's underlying medical condition, as many of these conditions portend a higher mortality. Furthermore, access to healthcare and other socioeconomic factors such as race, language, and level of education may have led to differences in both statin use and outcome. Because we did not measure plasma levels of these medications, we could not verify compliance with the stated medical regimen or assess absorption of the prescribed agent. Finally, our study is subject to the "healthyuser bias," as those who are prescribed medications for the management of chronic medical conditions and primary prophylaxis of cardiovascular disease may be healthier than those who are not prescribed medications for these reasons.
CONCLUSIONS
Sepsis and ALI are common syndromes with a high mortality. Statins are proven to be effective in the primary and secondary prevention of atherosclerotic cardiovascular disease, a condition which shares many pathophysiologic pathways with sepsis and ALI/ARDS. We found that prehospital statin use was associated with fewer diagnoses of sepsis and ALI/ARDS in patients admitted to the ICU with critical illness. Given the importance of these conditions, as well as the accepted safety profile and desirable effects of statin therapy, large, randomized, controlled trials should be undertaken to confirm these findings, similar to the studies of statin therapy in the prevention of venous thromboembolism (23) . In addition, aspirin may provide additional benefit, and further investigations should evaluate the possible additive effect of aspirin with statins on the prevention of these syndromes.
